First published 9/30/2026, 8:24:15 AM · Last updated 9/30/2026, 8:24:15 AM

Four-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer

A journal article published 2026-08-01 reporting a four-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab combined with chemotherapy for biliary tract cancer. The supplied excerpt contains no additional outcome, patient population, location, or impact details.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 2/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Long-term survival and safety data from a Phase 3 trial are relevant to clinicians, researchers, and decision-makers involved in biliary tract cancer care.

Sources

Four-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer

Report an issue